Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma
Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
The study will evaluate the safety and efficacy of AGN-210669 ophthalmic solution in
comparison with AGN-210669 vehicle and bimatoprost ophthalmic solution dosed once-daily each
morning, in subjects with ocular hypertension or primary open-angle glaucoma. Subjects will
be followed for 2 weeks.